{
    "id": 2554,
    "fullName": "RET V804L",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "RET V804L lies within the protein kinase domain of the Ret protein (UniProt.org). V804L confers a gain of function on the Ret protein, as indicated by increased kinase activity, cell transformation (PMID: 9242375), and is considered a gatekeeper mutation due to lack of response to some inhibitors, including cabozantinib and vandetanib (PMID: 27712045).",
            "references": [
                {
                    "id": 432,
                    "pubMedId": 9242375,
                    "title": "Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9242375"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 8444,
                    "pubMedId": 27712045,
                    "title": "Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27712045"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5979,
        "geneSymbol": "RET",
        "terms": [
            "RET",
            "CDHF12",
            "CDHR16",
            "HSCR1",
            "MEN2A",
            "MEN2B",
            "MTC1",
            "PTC",
            "RET-ELE1"
        ]
    },
    "variant": "V804L",
    "createDate": "11/11/2014",
    "updateDate": "10/17/2018",
    "referenceTranscriptCoordinates": {
        "id": 125424,
        "transcript": "NM_020975",
        "gDna": "chr10:g.43119548G>C",
        "cDna": "c.2410G>C",
        "protein": "p.V804L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6190,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804L (PMID: 26126987).",
            "molecularProfile": {
                "id": 2411,
                "profileName": "RET V804L"
            },
            "therapy": {
                "id": 4089,
                "therapyName": "Pz-1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5385,
                    "pubMedId": 26126987,
                    "title": "Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26126987"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3421,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing RET V804L demonstrated resistance to growth inhibition by Caprelsa (vandetanib) in culture (PMID: 15184865).",
            "molecularProfile": {
                "id": 2411,
                "profileName": "RET V804L"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3687,
                    "pubMedId": 15184865,
                    "title": "Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15184865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1851,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cell lines expressing RET V804L demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).",
            "molecularProfile": {
                "id": 2411,
                "profileName": "RET V804L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 602,
                    "pubMedId": 23811235,
                    "title": "Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23811235"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14456,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing KIF5B-RET and RET V804L were sensitive to treatment with Selpercatinib (LOXO-292) in culture, demonstrating decreased cell proliferation (PMID: 29912274).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11635,
                    "pubMedId": 29912274,
                    "title": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8723,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over-expressing RET V804L in the context of KIF5B-RET demonstrated reduced response to Iclusig (ponatinib) in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14414,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V804L in the context of KIF5B-RET were resistant to Ofev (nintedanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13757,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU-667 inhibited proliferation of cells expressing KIF5B-RET with RET V804L in culture, and inhibited tumor growth in xenograft models (PMID: 29657135).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 5530,
                "therapyName": "BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11266,
                    "pubMedId": 29657135,
                    "title": "Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29657135"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8717,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RET V804L in the context of KIF5B-RET conferred resistance to Cometriq (cabozantinib) in transformed cells in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3184,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Alecensa (alectinib) resulted in decreased autophosphorylation of Ret and reduced phosphorylation of Akt and Erk in transformed cells expressing both KIF5B-RET and RET V804L in culture (PMID: 25349307).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3119,
                    "pubMedId": 25349307,
                    "title": "Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25349307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8721,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over-expressing RET V804L in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8722,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over-expressing RET V804L in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2411,
            "profileName": "RET V804L",
            "profileTreatmentApproaches": [
                {
                    "id": 381,
                    "name": "RET Inhibitor",
                    "profileName": "RET V804L"
                }
            ]
        },
        {
            "id": 12734,
            "profileName": "KIF5B - RET RET V804L",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 125425,
            "transcript": "NM_020630",
            "gDna": "chr10:g.43119548G>C",
            "cDna": "c.2410G>C",
            "protein": "p.V804L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 125424,
            "transcript": "NM_020975",
            "gDna": "chr10:g.43119548G>C",
            "cDna": "c.2410G>C",
            "protein": "p.V804L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}